Ranbaxy Malaysia Counts On Hypertension Drug As Major Profit Driver
This article was originally published in PharmAsia News
Executive SummaryRanbaxy Malaysia anticipates its Covance (losartan) drug for the treatment of hypertension will be a major driver of profits over the next two years
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.